Market Place
Sourcing Support
Weekly News Recap #Phispers
Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight
Novartis signed two deals this week — a US$ 5.2 billion cardiology deal with China’s Argo Biopharmaceuticals, and a...
Impressions : 522
White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema
The Trump administration has fired US Centers for Disease Control and Prevention (CDC) Director Susan Monarez, post a policy di...
Impressions : 953
FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity
This week’s Phispers brings you updates on key drug approvals. The US Food and Drug Administration (FDA) has granted acce...
Impressions : 1221
FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad
The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...
Impressions : 1418
Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug
The US Food and Drug Administration (FDA) has granted an accelerated approval to Jazz Pharmaceuticals’ Modeyso, a drug th...
Impressions : 766
Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug
The US Food and Drug Administration (FDA) has approved PTC Therapeutics’ oral drug to treat a rare genetic disorder known...
Impressions : 906
Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year
AstraZeneca and Biogen are the latest drugmakers to
announce investments in the US to avoid import tariffs. AstraZeneca is
in...
Impressions : 1202
Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee
This week’s Phispers brings you updates on cell and gene therapies (CGTs). After the death of a second teenaged boy last ...
Impressions : 4246
Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal
The world of pharmaceuticals continued to witness large deals. Merck announced a US$ 10 billion acquisition of Verona Pharma, g...
Impressions : 659
AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem
This week in Phispers, AbbVie struck a deal worth up to US$ 2.1 billion to acquire Capstan Therapeutics and its innovative in v...
Impressions : 700
Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer
In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...
Impressions : 3010
Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC
This week’s Phispers comes with news on several M&A deals. Eli Lilly made headlines with its US$ 1.3 billion acquisition ...
Impressions : 668
RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials
This week, US Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...
Impressions : 1106
BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn
The pharmaceutical sector saw several significant deals with major players expanding their portfolios. Bristol Myers Squibb (BM...
Impressions : 579
Lilly expands pain pipeline via US$ 1 bn SiteOne buyout; US cancels funding for Moderna’s bird flu vaccine
In news this week, Eli Lilly has placed a billion-dollar bet on non-opioid pain management by acquiring SiteOne Therapeutics fo...
Impressions : 703
Pfizer inks US$ 6 bn oncology deal with China’s 3SBio; BioNTech to invest US$ 1.3 bn in UK for new R&D, AI centers
In news this week, Pfizer announced a US$ 6 billion licensing agreement with China’s 3SBio, securing global rights to a p...
Impressions : 723
Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US
The US President Donald Trump’s dramatic intervention in pharmaceutical pricing took centerstage as the White House unvei...
Impressions : 798
BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies
US President Donald Trump’s tariff threats appear to be working, as Bristol Myers Squibb became the latest drugmaker to a...
Impressions : 1725
AbbVie, Amgen, Thermo Fisher to invest in US manufacturing to avoid tariffs; Merck KGaA acquires SpringWorks for US$ 3.9 bn
Ever since US President Donald Trump has talked about a “major tariff” on drug imports coming “very shortly&r...
Impressions : 948
Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm
After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...
Impressions : 1119
Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill
After Eli Lilly and
Johnson & Johnson, Novartis has become the latest big pharma to announce
mega investments in the US. The ...
Impressions : 982
Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology
In this week’s news, US President Donald Trump has said “major” pharmaceutical import tariffs are coming soon...
Impressions : 1151
CBER director forced out in FDA gutting; Sanofi, Alnylam’s RNAi therapy Qfitlia wins US approval for hemophilia A, B
The pharma industry saw its most tumultuous week in the recent past with the US Food and Drug Administration (FDA) facing an un...
Impressions : 1045
J&J plans US$ 55 bn investment in US to avoid Trump’s tariffs; Astra to invest US$ 2.5 bn in Chinese R&D centre
This week’s Phispers brings you lots of news from China. AstraZeneca is investing US$ 2.5 billion in a new Beijing resear...
Impressions : 923
Mallinckrodt, Endo merge in US$ 6.7 bn deal; Astra buys cell therapy developer EsoBiotec; Pfizer sells entire stake in Haleon
In Phispers this week, two drugmakers emerging from bankruptcy — Mallinckrodt and Endo — are merging in order to le...
Impressions : 1223
Roche buys rights to Zealand’s obesity med in US$ 5.3 bn deal; Merck wins Gardasil lawsuit, bolsters vaccine manufacturing
In news this week, Roche has acquired rights to develop and commercialize Zealand Pharma’s experimental obesity drug petr...
Impressions : 1275
AbbVie enters obesity race with US$ 2.23 bn deal with Denmark’s Gubra; Roche’s TNKase approved for treating strokes
AbbVie has forayed into the obesity treatment market with a US$ 2.23 billion licensing deal with Denmark’s Gubra for its ...
Impressions : 984
Lilly to invest US$ 27 bn in US as Trump threatens big pharma with tariffs; FDA scrambles to rehire after mass layoffs
In the US, President Donald Trump has been putting
pressure on Big Pharma to reshore or face tariffs.
Eli Lilly has been the ...
Impressions : 1074
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.